查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612525

β阻断剂市场：按类型、应用和分销管道划分 - 2025-2030 年全球预测

Beta Blockers Market by Type (Beta Non-selective Blocker, Beta-1 Selective Blocker), Application (Cardiac Diseases, Glaucoma, Hypertension), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年β阻断剂市值为105.4亿美元，预计2024年将达到110.6亿美元，复合年增长率为5.23%，到2030年将达到150.8亿美元。

β阻断剂或β-肾上腺素阻断剂是主要用于治疗各种心血管疾病的药物，包括高血压、心律不整和心臟衰竭。其范围也扩展到治疗焦虑、偏头痛和某些类型的青光眼，凸显了其需求和多功能性。这些药物透过抑制肾上腺素的作用、降低心率和血压来发挥作用。心血管疾病盛行率上升、人口老化以及人们对治疗选择的认识不断提高，推动了β阻断剂的全球市场。 β阻断剂在医院、诊所和零售药局都有应用，展示了其广泛的最终用途。配方技术的进步、医疗保健支出的增加以及加强公共卫生基础设施的努力对产业成长产生了重大影响。学名药的兴起为新兴市场带来了潜在的商机，促进了竞争性定价和扩大了准入范围。公司可以透过投资创新的药物输送系统并开拓开拓的当地市场来利用这些动态。然而，它面临着监管障碍、严格的药物核准以及与长期使用相关的副作用等挑战，这可能会阻碍市场成长。此外，某些地区的经济不稳定可能会影响医疗保健预算，最终影响药品购买。在创新和研究方面，开发具有更少或更多针对性副作用的递送系统可以提供竞争优势。此外，专注于遗传因素和生活习惯以实现更有效治疗的个人化医疗方法是成熟的研究领域。该市场的特点是竞争激烈，主要企业不断投资研发以维持和扩大市场占有率。因此，希望发展β阻断剂市场的公司必须专注于创新、策略伙伴关係关係，并扩大其在开拓市场的影响力，以利用新的机会。

主要市场统计
基准年[2023] 105.4亿美元
预测年份 [2024] 110.6亿美元
预测年份 [2030] 150.8亿美元
复合年增长率（%） 5.23%

市场动态：快速发展的β阻断剂市场的关键市场洞察

供需的动态交互作用正在改变β阻断剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 人口老化加剧，更容易罹患心臟病
    • β阻断剂在治疗郁血性心臟衰竭、心律不整和甲状腺功能亢进中的作用日益增强
    • 政府和医疗保健组织的公共卫生倡议和意识提升计划
  • 市场限制因素
    • 发生产品召回事件
  • 市场机会
    • 活性化活动以开发治疗高血压的个人化β阻断剂
    • β阻断剂新分析方法的趋势
  • 市场挑战
    • 与服用β阻断剂相关的副作用

波特的五力：驾驭β阻断剂市场的策略工具

波特的五力架构是了解β阻断剂市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解β阻断剂市场的外部影响

外部宏观环境因素在塑造β阻断剂市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解β阻断剂市场的竞争状况

对β阻断剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵β阻断剂市场供应商的绩效评估

FPNV 定位矩阵是评估β阻断剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为β阻断剂市场的成功指明道路

对于旨在加强在全球市场的影响力的公司来说， β阻断剂市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着人口老化，人们更容易罹患心臟病
      • β阻断剂在治疗郁血性心臟衰竭、心律不整和甲状腺功能亢进中的作用日益增强
      • 政府和医疗机构的公共卫生倡议和意识计划
    • 抑制因素
      • 产品召回发生率
    • 机会
      • 扩大研发 (R&D) 活动，开发个人化的β阻断剂治疗高血压
      • β阻断剂分析方法的新趋势
    • 任务
      • 与服用β阻断剂相关的副作用
  • 市场区隔分析
    • 类型：增加 β1-选择性阻断剂的消费量以解决呼吸道疾病问题
    • 应用：越来越多地使用β阻断剂作为肾上腺素来治疗各种心血管疾病
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章β阻断剂市场：依类型

  • Beta非选择性阻断剂
    • 拉贝洛尔
    • 硫酸戊布醇
    • 吲哚洛尔
    • 盐酸索他洛尔
  • beta1选择性阻断剂
    • 醋丁洛尔
    • 阿替洛尔
    • 比索洛尔
    • 美托洛尔

第七章β阻断剂市场：依应用分类

  • 心臟病
    • 心绞痛
    • 心房颤动
    • 心臟衰竭
  • 青光眼
  • 高血压

第 8 章β阻断剂市场：按分销管道

  • 医院药房
  • 零售药房

第九章 美洲β阻断剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区β阻断剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的β阻断剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准VELSIPITY 用于治疗活动性溃疡性大肠炎
    • “一种新的超短效β受体阻断剂兰地洛尔已在加拿大获得核准用于治疗严重的心臟病。”
    • Ajanta Pharma 推出新型双效片剂“Met-XL AMT”，用于简单有效的高血压管理
  • 战略分析和建议

公司名单

  • AdvaCare Pharma
  • Amneal Pharmaceuticals LLC
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Dr. Reddy's Laboratories Ltd.
  • Eagle Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Neuracle Lifesciences Private Limited
  • Novartis AG
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica SpA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Menarini Group
  • Viatris Inc.
Product Code: MRR-7A22CB0E64F1

The Beta Blockers Market was valued at USD 10.54 billion in 2023, expected to reach USD 11.06 billion in 2024, and is projected to grow at a CAGR of 5.23%, to USD 15.08 billion by 2030.

Beta blockers, or beta-adrenergic blocking agents, are pharmaceuticals primarily used to manage various cardiovascular conditions, including hypertension, arrhythmias, and heart failure. Their scope extends into treating anxiety, migraines, and certain types of glaucoma, highlighting their necessity and versatility. These medications function by inhibiting the effects of adrenaline, resulting in lowered heart rates and blood pressure. The global market for beta blockers is driven by rising cardiovascular disease prevalence, aging populations, and increasing awareness of treatment options. The application of beta blockers spans hospitals, clinics, and retail pharmacies, demonstrating their extensive end-use scope. Industry growth is significantly influenced by technological advancements in drug formulations, increasing healthcare spending, and initiatives to enhance public health infrastructure. The rise in generic drug formulations presents potential opportunities in emerging markets, encouraging competitive pricing and widening access. Companies can leverage these dynamics by investing in innovative drug delivery systems or exploring untapped rural markets. However, the market faces challenges, such as regulatory hurdles, strict drug approvals, and side effects associated with long-term use, which could inhibit growth. Additionally, economic instability in certain regions can impact healthcare budgets and, consequently, pharmaceutical purchases. In terms of innovation and research, developing beta blockers with fewer side effects or targeted delivery systems could offer a competitive edge. Furthermore, personalized medicine approaches, focusing on genetic and lifestyle factors for more effective treatment, present an area ripe for research. The market is characterized by high competition, with key players constantly investing in R&D to maintain or increase market share. Thus, businesses aiming for growth in the beta blockers market should focus on innovation, strategic partnerships, and expanding their presence in underserved markets to capitalize on unfolding opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 10.54 billion
Estimated Year [2024] USD 11.06 billion
Forecast Year [2030] USD 15.08 billion
CAGR (%) 5.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Beta Blockers Market

The Beta Blockers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population more susceptible to heart-related conditions
    • Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
    • Public health initiatives and awareness programs by governments and healthcare organizations
  • Market Restraints
    • Incidence of product recall
  • Market Opportunities
    • Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
    • Novel trends in analytical methods for beta blockers
  • Market Challenges
    • Side effects associated with the consumption of beta blockers

Porter's Five Forces: A Strategic Tool for Navigating the Beta Blockers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Beta Blockers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Beta Blockers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Beta Blockers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Beta Blockers Market

A detailed market share analysis in the Beta Blockers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Beta Blockers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Beta Blockers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Beta Blockers Market

A strategic analysis of the Beta Blockers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Blockers Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, Amneal Pharmaceuticals LLC, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals, Inc., GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., Neuracle Lifesciences Private Limited, Novartis AG, Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Menarini Group, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Beta Blockers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Beta Non-selective Blocker and Beta-1 Selective Blocker. The Beta Non-selective Blocker is further studied across Labetalol, Penbutolol Sulfate, Pindolol, and Sotalol Hydrochloride. The Beta-1 Selective Blocker is further studied across Acebutolol, Atenolol, Bisoprolol, and Metoprolol.
  • Based on Application, market is studied across Cardiac Diseases, Glaucoma, and Hypertension. The Cardiac Diseases is further studied across Angina, Atrial Fibrillation, and Heart Failure.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population more susceptible to heart-related conditions
      • 5.1.1.2. Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
      • 5.1.1.3. Public health initiatives and awareness programs by governments and healthcare organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Incidence of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
      • 5.1.3.2. Novel trends in analytical methods for beta blockers
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the consumption of beta blockers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising consumption of beta-1 selective blockers to address respiratory concerns
    • 5.2.2. Application: Increasing usage of beta blockers as an adrenaline in managing various cardiovascular conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Beta Blockers Market, by Type

  • 6.1. Introduction
  • 6.2. Beta Non-selective Blocker
    • 6.2.1. Labetalol
    • 6.2.2. Penbutolol Sulfate
    • 6.2.3. Pindolol
    • 6.2.4. Sotalol Hydrochloride
  • 6.3. Beta-1 Selective Blocker
    • 6.3.1. Acebutolol
    • 6.3.2. Atenolol
    • 6.3.3. Bisoprolol
    • 6.3.4. Metoprolol

7. Beta Blockers Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiac Diseases
    • 7.2.1. Angina
    • 7.2.2. Atrial Fibrillation
    • 7.2.3. Heart Failure
  • 7.3. Glaucoma
  • 7.4. Hypertension

8. Beta Blockers Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Retail Pharmacies

9. Americas Beta Blockers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Beta Blockers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Beta Blockers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approved VELSIPITY, An Advancement To Treat Active Ulcerative Colitis
    • 12.3.2. "New Ultra-Short-Acting Beta Blocker, Landiolol, Received Canadian Approval For Critical Care Cardiac Conditions
    • 12.3.3. Ajanta Pharma Launched Met-XL AMT, A New Dual-Action Tablet for Simplified and Effective Hypertension Management
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AdvaCare Pharma
  • 2. Amneal Pharmaceuticals LLC
  • 3. ANI Pharmaceuticals, Inc.
  • 4. AstraZeneca PLC
  • 5. Baxter International Inc.
  • 6. Bayer AG
  • 7. Boehringer Ingelheim International GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Cipla Limited
  • 10. DAIICHI SANKYO COMPANY, LIMITED
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eagle Pharmaceuticals, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Lupin Limited
  • 15. Merck & Co., Inc.
  • 16. Neuracle Lifesciences Private Limited
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Recordati Industria Chimica e Farmaceutica S.p.A.
  • 20. Sun Pharmaceutical Industries Ltd.
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. The Menarini Group
  • 23. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BETA BLOCKERS MARKET RESEARCH PROCESS
  • FIGURE 2. BETA BLOCKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BETA BLOCKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BETA BLOCKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY LABETALOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY PENBUTOLOL SULFATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY PINDOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BETA BLOCKERS MARKET SIZE, BY SOTALOL HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BETA BLOCKERS MARKET SIZE, BY ACEBUTOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BETA BLOCKERS MARKET SIZE, BY BISOPROLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BETA BLOCKERS MARKET SIZE, BY METOPROLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BETA BLOCKERS MARKET SIZE, BY ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BETA BLOCKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BETA BLOCKERS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BETA BLOCKERS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BETA BLOCKERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BETA BLOCKERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 281. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 282. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023